Search company, investor...

Syros Pharmaceuticals



Total Raised


About Syros Pharmaceuticals

Syros Pharmaceuticals (NASDAQ: SYRS) is a therapeutics company working in gene control to develop the treatment of cancer and other diseases. It includes three investigational medicines in clinical development and multiple programs in preclinical development and discovery research. The company is based in Cambridge, Massachusetts.

Headquarters Location

35 CambridgePark Drive 4th Floor

Cambridge, Massachusetts, 02140,

United States


Missing: Syros Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Syros Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Syros Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Syros Pharmaceuticals is included in 2 Expert Collections, including Cancer.



4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.


Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Syros Pharmaceuticals Patents

Syros Pharmaceuticals has filed 44 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Proteins
  • Clusters of differentiation
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Intracellular receptors, Antineoplastic drugs, Retinoids, Experimental cancer drugs


Application Date


Grant Date



Related Topics

Transcription factors, Intracellular receptors, Antineoplastic drugs, Retinoids, Experimental cancer drugs



Latest Syros Pharmaceuticals News

RAPT Therapeutics, Repare Therapeutics, GlycoMimetics among biotechs to disclose exposure to Silicon Valley Bank

Mar 13, 2023

GlycoMimetics ( GLYC ) currently holds cash deposits of ~$2 million at Silicon Valley Bank ( SIVB ), which the company considers to be immaterial to its liquidity, according to an SEC filing . Syros Pharmaceuticals ( SYRS ) discloses that it has two deposit accounts at Silicon Valley Bank . One of these accounts has a balance of less than $250,000, and the other has a balance of ~$3.1 million pursuant to a letter of credit, which amount is classified as restricted cash on the Company’s consolidated balance sheet as of December 31, 2022, according to an SEC filing. SYRS reaffirms its estimate that its cash, cash equivalents and marketable securities will be sufficient to fund its planned operating expense and capital expenditure requirements into the second quarter of 2025. Aptose does not believe these amounts represent a material portion of its cash and cash equivalents. The company does not expect any material impact on operations, payroll, or ongoing clinical trials. Among pharma, Wave Life Sciences ( WVE ) considers its direct exposure to SVB’s receivership as immaterial , given that the aggregate amount of the company’s cash and restricted cash held at SVB is ~$1.5 million, which is below the FDIC-insured amount of $250,000, according to an SEC filing.

Syros Pharmaceuticals Frequently Asked Questions (FAQ)

  • Where is Syros Pharmaceuticals's headquarters?

    Syros Pharmaceuticals's headquarters is located at 35 CambridgePark Drive, Cambridge.

  • What is Syros Pharmaceuticals's latest funding round?

    Syros Pharmaceuticals's latest funding round is PIPE.

  • How much did Syros Pharmaceuticals raise?

    Syros Pharmaceuticals raised a total of $124.4M.

  • Who are the investors of Syros Pharmaceuticals?

    Investors of Syros Pharmaceuticals include Ally Bridge Group, EcoR1 Capital, OrbiMed Advisors, Samsara BioCapital, Bain Capital and 16 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.